Is NCT04899102 recruiting in Boston, MA?

Yes, NCT04899102 is currently recruiting participants at its Boston, MA location. This fatty liver clinical trial is actively enrolling qualified participants.

How do I join the fatty liver clinical trial in Boston?

To join this clinical trial in Boston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Boston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Fatty Liver Clinical Trial in Boston, MA

About This Fatty Liver Study in Boston

NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

Willing and able to provide informed consent

Age 18 years or older at time of consent

BMI 23-30kg/m\^2 at screening

Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:

Grade \>=1 steatosis on clinical liver biopsy; OR

Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)

Liver fat fraction ≥10% on H-MRS performed during the screening period

Hepatitis C antibody and Hepatitis B surface antigen negative at screening

Exclusion Criteria

Heavy alcohol use for at least 3 consecutive months within the past 5 years prior to screening \[heavy alcohol consumption is defined as: \> 20g daily for women or \> 30mg daily for men, assessed by the Lifetime Drinking History assessment at screening (23, 24)\].

Evidence of other known forms of chronic liver disease including: • Alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).

Current or prior history of Type II Diabetes requiring insulin or sulfonylureas due to risk of hypoglycemia with fasting.

Use of any pharmacological treatments for NAFLD/NASH within the 6 months prior to the screening visit, except vitamin E. Patients on a stable dose of vitamin E can be enrolled in the study.

Unstable body weight \[defined as: \>10% reduction in body weight in the 6 months prior to the screening visit\]

Known cirrhosis, stage 4 fibrosis on prior liver biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam.

Current or prior history of Child-Pugh score ≥7.

History of liver transplant, or current placement on a liver transplant list.

Known positivity for human immunodeficiency virus infection.

Prior or planned bariatric surgery, patients on active pharmacological treatment for weight loss, or active involvement in a weight loss program.

Routine MRI exclusion criteria, such as the presence of a pacemaker or cerebral aneurysm clip.

Chronic Kidney Disease (CKD) with eGFR \< 60.

For women of child-bearing potential (WOCBP): positive urine hCG, trying to achieve pregnancy, or breastfeeding \[a negative urine pregnancy test is required at screening for women of child-bearing potential\].

Other medical conditions or severe chronic illnesses that, in the opinion of the Investigator, may present a contraindication to study participation.

Any other condition that, in the opinion of the Investigator, may hinder study compliance or completion of the study schedule of assessments.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT04899102) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Fatty Liver Treatment Options in Boston, MA

If you're searching for fatty liver treatment options in Boston, MA, this clinical trial (NCT04899102) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fatty liver specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all fatty liver clinical trials near you to find additional studies recruiting in your area.

Fatty Liver Clinical Trial in Boston, MA

Expert Care in Boston

IRB Approved

No-Cost Care

Apply for This Boston Location

Why Participate?

Simple Process